%0 Journal Article %A Sehoon Park %A Soojin Lee %A Yaerim Kim %A Semin Cho %A Kwangsoo Kim %A Yong Chul Kim %A Seung Seok Han %A Hajeong Lee %A Jung Pyo Lee %A Soryoung Lee %A Eue-Keun Choi %A Kwon Wook Joo %A Chun Soo Lim %A Yon Su Kim %A Dong Ki Kim %T Causal effect of atrial fibrillation on brain white or grey matter volume: A Mendelian randomization study %D 2020 %R 10.1101/2020.12.17.20248314 %J medRxiv %P 2020.12.17.20248314 %X Background Atrial fibrillation (AF) and brain volume loss are prevalent in older individuals. Further study investigating the causal effect of AF on brain volume is warranted.Methods This study was a Mendelian randomization (MR) analysis. The genetic instrument for AF was constructed from a previous genome-wide association study (GWAS) meta-analysis and included 537,409 individuals of European ancestry. The outcome summary statistics for quantile-normalized white or grey matter volume measured by magnetic resonance imaging were provided by the previous GWAS of 8426 white British UK Biobank participants. The main MR method was the inverse variance weighted method, supported by sensitivity MR analysis including MR-Egger regression and the weighted median method. The causal estimates from AF to white or grey matter volume were further adjusted for effects of any stroke or ischemic stroke by multivariable MR analysis.Results A higher genetic predisposition for AF (one standard deviation increase) was significantly associated with lower white matter volume [beta −0.128 (−0.208, −0.048)] but not grey matter volume [beta −0.041 (−0.101, 0.018)], supported by all utilized sensitivity MR analyses. The multivariable MR analysis indicated that AF is causally linked to lower white matter volume independent of the stroke effect.Conclusions AF is a causative factor for white matter volume loss. The effect of AF on grey matter volume was inapparent in this study. A future trial is necessary to confirm whether appropriate AF management can be helpful in preventing cerebral white matter volume loss or related brain disorders in AF patients.Competing Interest StatementEKC: research grants from Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daiichi-Sankyo, Dreamtech Co. Ltd., Medtronic, Samjinpharm, Sanofi-Aventis, Seers Technology, Skylabs, and Yuhan. No fees are received personally.Funding StatementThis work was supported by the Industrial Strategic Technology Development Program - Development of bio-core technology (10077474, Development of early diagnosis technology for acute/chronic renal failure) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from SNU R&DB Foundation (800-20190571). The study was performed independently by the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review boards of Seoul National University Hospital (No. E-2012-004-1177) and the UK Biobank consortium (application No. 53799). The study was performed in accordance with the Declaration of Helsinki. The study was performed by utilizing available public databases or GWAS summary statistics from previously published studies; thus, the requirement for informed consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for this study will be made available through the UK Biobank. The implemented GWAS summary statistics are available in the public domain. %U https://www.medrxiv.org/content/medrxiv/early/2020/12/19/2020.12.17.20248314.full.pdf